Cytek Biosciences (CTKB) Other Non-Current Liabilities (2020 - 2026)

Cytek Biosciences' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• Quarterly Other Non-Current Liabilities fell 72.81% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 72.81% YoY) and the FY2025 annual result came in at $2.3 million, down 2.41% from the prior year.
• Other Non-Current Liabilities was $2.4 million for Q1 2026 at Cytek Biosciences, up from $2.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $16.9 million in Q2 2024 and bottomed at $1.1 million in Q1 2022.
• A 5-year average of $5.3 million and a median of $2.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 1116.7% in 2023, while the deepest fall reached 84.89% in 2023.
• Cytek Biosciences' Other Non-Current Liabilities stood at $1.6 million in 2022, then soared by 53.18% to $2.4 million in 2023, then decreased by 2.76% to $2.4 million in 2024, then slipped by 2.41% to $2.3 million in 2025, then advanced by 3.94% to $2.4 million in 2026.
• Business Quant data shows CTKB's Other Non-Current Liabilities at $2.4 million in Q1 2026, $2.3 million in Q4 2025, and $2.5 million in Q3 2025.